New Minoxidil Formulation Improves Hair Growth in Women With Female-Pattern Loss

New clinical data from Veradermics offers a potential shift for women struggling with androgenetic alopecia. In a phase 2 open-label trial, an extended-release formulation of minoxidil known as VDPHL01 produced measurable hair regrowth in approximately 90% of female participants over six months.

The study involved 28 women who received either a once-daily or twice-daily dose of 4.5 mg of the drug. Results measured via the Androgenetic Alopecia Impact Rating Scale showed significant improvement in 88.9% of the once-daily group and 90% of the twice-daily group. Investigators and participants noted these visible changes as early as two months into the trial.

According to the company, the treatment was well tolerated across all clinical study participants. Data showed no serious adverse events and no signals related to cardiovascular issues, which remain a primary concern for patients considering oral minoxidil therapies. While low-dose oral minoxidil is often used off-label for hair loss, this specific formulation aims to provide a targeted, extended-release option.

Experts familiar with hair disorders suggest these findings address a major gap in dermatological care. Many current treatments for female-pattern thinning require half a year or more to show results. The rapid onset of benefit seen in this trial stands out compared to standard therapies currently available on the market.

Veradermics is moving forward with additional phase 2 and 3 trials for both men and women. While these early results are promising, the medical community expects more definitive data by the first half of 2027. This development represents a key step toward expanding non-hormonal options for those experiencing progressive hair thinning.